Benfotiamine in Alzheimer's Disease: A Pilot Study
Burke Rehabilitation Hospital is currently conducting a clinical trial to evaluate whether increasing brain glucose utilization can slow cognitive decline in patients with Amnestic Mild Cognitive Impairment or mild Alzheimer's disease dementia.
Thiamine (vitamin B1) is closely linked to glucose metabolism, which is important to maintain memory and cognition. Many thiamine dependent processes are diminished in Alzheimer’s disease and reduced glucose utilization is one of the early symptoms of the development of Alzheimer’s disease. The goal of this trial is to determine if increasing brain thiamine availability with the new investigational drug benfotiamine will minimize the decline in glucose utilization and slow the cognitive decline associated with Alzheimer’s disease.
Individuals who are at least 60 years old and with a diagnosis of Amnestic Cognitive Impairment or Alzheimer's disease may be eligible for participation. During this study we will give you a complete neurological exam, conduct tests of memory, learning and other cognitive functions, draw blood for laboratory measures, and use imaging to examine the presence of amyloid (plaques) in your brain and also the amount of glucose that your brain is using.
Study participation will be over a 12 month period and will include follow-up visits to our clinic every 3 months. There are no costs associated with participation in this study.
Burke Rehabilitation Center is the designated location for this study. If you would like more information regarding this study, please contact Rosanna Cirio, MA at 914-597-2476 or email@example.com.
Individuals who are at least 60 years old and with a diagnosis of Amnestic Cognitive Impairment or Alzheimer's disease may be eligible for participation.